For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Aboyans Victor    | **Payment from healthcare industry**: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.  
Astrazeneca : Chronic Heart Failure  
Bayer Healthcare : Peripheral Vascular and Cerebrovascular Disease, Risk Factors and Prevention  
Novo-Nordisk : Risk Factors and Prevention  
Amarin : Risk Factors and Prevention  
Boehringer Ingelheim : Risk Factors and Prevention  
Organon : Risk Factors and Prevention  
**Membership or affiliation in political or advocacy groups working in the field of cardiology.**  
I am a board member of the French Society of Cardiology, and the French Federation of Cardiology. |
| Agewall Stefan     | **Ongoing research funding from public and/or not-for-profit organisations** (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one’s ability to join an ESC activity  
EU Horizon                                                                                                                                                  |
| Auricchio Angelo  | **Payment from healthcare industry**: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.  
Boston Scientific : Arrhythmias, General  
Medtronic : Arrhythmias, General  
Philips : Arrhythmias, General  
Microport (CRM) : Arrhythmias, General  
Cairdac : Arrhythmias, General  
XSpline : Arrhythmias, General |
| Back Magnus       | **Payment from healthcare industry to your department or institution or any other body for your personal services**: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.  
Novartis : Risk Factors and Prevention  
Amarin : Risk Factors and Prevention |
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehm Michael</td>
<td>2023</td>
</tr>
</tbody>
</table>
|                      | **Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.**  
Abbott : Chronic Heart Failure, Hypertension  
Amgen : Chronic Heart Failure, Hypertension  
Astra Zeneca : Chronic Heart Failure, Hypertension  
Bayer : Chronic Heart Failure, Hypertension  
Boehringer-Ingelheim : Chronic Heart Failure, Hypertension  
Medtronic : Chronic Heart Failure, Hypertension  
Novartis : Chronic Heart Failure, Hypertension  
Servier : Chronic Heart Failure, Hypertension  
Vifor International : Chronic Heart Failure, Hypertension  
Bristol Myers Squibb : Chronic Heart Failure, Hypertension  
Cytokinetics : Chronic Heart Failure, Hypertension |
| Bruining Nico        | 2023                               |
|                      | **Nothing to be declared**         |
| Capodanno Davide     | 2023                               |
|                      | **Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.**  
Terumo Inc : Interventional Cardiology  
Sanofi Aventis : Interventional Cardiology  
Sanofi Aventis : Pharmacology and Pharmacotherapy  
Novo Nordisk : Pharmacology and Pharmacotherapy  
**Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.**  
Medtronic : Interventional Cardiology |
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Crea Filippo            | **Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.**  
                          | Amgen : Acute Coronary Syndromes  
                          | Astra Zeneca : Acute Coronary Syndromes  
                          | Novo-Nordisk : Acute Coronary Syndromes  
                          | **Receipt of royalties for intellectual property.**  
                          | Wolters Kluwer : Acute Coronary Syndromes  
                          | Edra SPA - Masson : Acute Coronary Syndromes  |
| Ferrari Roberto         | **Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.**  
                          | Servier : Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes, Hypertension, Risk Factors and Prevention  
                          | Lupin : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes, Hypertension, Risk Factors and Prevention  
                          | Sunpharma : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes, Hypertension, Risk Factors and Prevention  
                          | Merck Serono : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes, Hypertension, Risk Factors and Prevention  
                          | **Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.**  
                          | Healthcare - Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Hypertension, Risk Factors and Prevention - Medical Trials Analysis  
                          | Employment (including part time) in healthcare industry during the year for which you are declaring.  
                          | Medical Trials Analysis : Scientific Director  
                          | Membership or affiliation in political or advocacy groups working in the field of cardiology.  
                          | Heart Failure Association  
                          | Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).  
                          | Director of Art Research and Science Srl (A.R.S.1) |
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gimelli Alessia</td>
<td>2023 Nothing to be declared</td>
</tr>
<tr>
<td>Guzik Tomasz</td>
<td>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Modera : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure. Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Chair; British Atherosclerosis Society</td>
</tr>
<tr>
<td>Maurer Gerald</td>
<td>2023 Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Echocardiography - Orcasonics Innovation Ltd.</td>
</tr>
<tr>
<td>Moons Philip</td>
<td>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : e-Cardiology/Digital Health</td>
</tr>
</tbody>
</table>
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Ponikowski Piotr   | 2023  
 | **Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one’s ability to join an ESC activity**  
 | Medical Research Agency  
 | **Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.**  
 | Pharmacosmos : Chronic Heart Failure  
 | Astra Zeneca : Chronic Heart Failure, Acute Heart Failure  
 | Bayer : Chronic Heart Failure, Acute Heart Failure  
 | Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure  
 | Novartis : Chronic Heart Failure, Acute Heart Failure  
 | Pfizer : Chronic Heart Failure, Acute Heart Failure  
 | Servier : Chronic Heart Failure, Acute Heart Failure  
 | Vifor International : Chronic Heart Failure, Acute Heart Failure  
 | Abbott Vascular : Chronic Heart Failure, Acute Heart Failure  
 | Novo-Nordisk : Chronic Heart Failure, Acute Heart Failure  |
| Sommer Philipp     | 2023  
 | **Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one’s ability to join an ESC activity**  
 | Fresenius Stiftung  
 | **Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.**  
 | Edwards Lifesciences : Arrhythmias, General  
 | Medtronic : Arrhythmias, General  
 | Abbott : Atrial Fibrillation (AF)  
 | Boston Scientific : Atrial Fibrillation (AF)  
 | Biosense Webster : Atrial Fibrillation (AF)  
 | **Membership or affiliation in political or advocacy groups working in the field of cardiology.**  
 | Member of DGK, HRS, EHRA, ESC  |
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Timmis Adam D       | **Receipt of royalties for intellectual property.**  
|                     | ALCS : Other  
|                     | Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.  
|                     | Healthcare - Other - I own shares in 2 start-up companies - I have received NO income from these investments 1. HD Clinical - Electronic health record system 2. RE-COGNITION Health Ltd - Dementia care unit |
| Vranckx Pascal      | **Nothing to be declared**                                                                         |